Ravaud A. Motzer R.J. Pandha H.S. et al.

Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy.

N Engl J Med. 375: 2246-2254Choueiri T.K. Tomczak P. Park S.H. et al.

Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma.

N Engl J Med. 385: 683-694Heng D.Y.C. Xie W. Regan M.M. et al.

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.

J Clin Oncol. 27: 5794-5799Motzer R.J. Bacik J. Murphy B.A. et al.

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma.

J Clin Oncol. 20: 289-296Mekhail T.M. Abou-Jawde R.M. BouMerhi G. et al.

Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma.

J Clin Oncol. 23: 832-841Manola J. Royston P. Elson P. et al.

Prognostic model for survival in patients with metastatic renal cell carcinoma: Results from the international kidney cancer working group.

Clin Cancer Res. 17: 5443-5450Heng D.Y.C. Xie W. Regan M.M. et al.

External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study.

Lancet Oncol. 14: 141-148Kroeger N. Xie W. Lee J.L. et al.

Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria.

Cancer. 119: 2999-3006McKay R.R. Kroeger N. Xie W. et al.

Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy.

Eur Urol. 65: 577-584Tugues S. Koch S. Gualandi L. et al.

Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer.

Mol Aspects Med. 32: 88-111Turajlic S. Xu H. Litchfield K. et al.

Tracking cancer evolution reveals constrained routes to metastases: TRACERx renal.

Cell. 173: 581-594.e12Harmon C.S. Deprimo S.E. Figlin R.A. et al.

Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma.

Cancer Chemother Pharmacol. 73: 151-161Peña C. Lathia C. Shan M. et al.

Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III treatment approaches in renal cancer global evaluation trial.

Clin Cancer Res. 16: 4853-4863Escudier B. Eisen T. Stadler W.M. et al.

Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

J Clin Oncol. 27: 3312-3318Zurita A.J. Jonasch E. Wang X. et al.

A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma.

Ann Oncol. 23: 46-52Tran H.T. Liu Y. Zurita A.J. et al.

Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials.

Lancet Oncol. 13: 827-837Liu Y. Tran H.T. Lin Y. et al.

Circulating baseline plasma cytokines and angiogenic factors (CAF) as markers of tumor burden and therapeutic response in a phase III study of pazopanib for metastatic renal cell carcinoma (mRCC).

J Clin Oncol. 29: 4553Hahn A.W. Nussenzveig R.H. Maughan B.L. et al.

Cell-free circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): current knowledge and potential uses.

3 (1). Kidney Cancer, : 7-13Nuzzo P.V. Berchuck J.E. Korthauer K. et al.

Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes.

Nat Med. 26: 1041-1043Pal S.K. Sonpavde G. Agarwal N. et al.

Evolution of circulating tumor DNA profile from first-line to subsequent therapy in metastatic renal cell carcinoma.

Eur Urol. 72: 557-564Kotecha R.R. Gedvilaite E. Ptashkin R. et al.

Matched molecular profiling of cell-free dna and tumor tissue in patients with advanced clear cell renal cell carcinoma.

JCO Precis Oncol. 6: e2200012

Yamamoto Y, Uemura M, Nakano K, et al. Increased level and fragmentation of plasma circulating cell-free DNA are diagnostic and prognostic markers for renal cell carcinoma. 2018.

Lu H. Busch J. Jung M. et al.

Diagnostic and prognostic potential of circulating cell-free genomic and mitochondrial DNA fragments in clear cell renal cell carcinoma patients.

Clinica Chim Acta. 452: 109-119https://doi.org/10.1016/j.cca.2015.11.009Skrypkina I. Tsyba L. Onyshchenko K. et al.

Concentration and methylation of cell-free DNA from blood plasma as diagnostic markers of renal cancer.

Dis Markers. 2016https://doi.org/10.1155/2016/3693096Morrissey J.J. Mobley J. Song J. et al.

Urinary concentrations of aquaporin-1 and perilipin-2 in patients with renal cell carcinoma correlate with tumor size and stage but not grade.

Urology. 83 ()Treiber T. Treiber N. Meister G.

Regulation of microRNA biogenesis and its crosstalk with other cellular pathways.

Nat Rev Mol Cell Biol. 20: 5-20Youssef Y.M. White N.M.A. Grigull J. et al.

Accurate molecular classification of kidney cancer subtypes using microRNA signature.

Eur Urol. 59: 721-730White N.M.A. Bao T.T. Grigull J. et al.

miRNA profiling for clear cell renal cell carcinoma: biomarker discovery and identification of potential controls and consequences of miRNA dysregulation.

J Urol. 186: 1077-1083Wotschofsky Z. Busch J. Jung M. et al.

Diagnostic and prognostic potential of differentially expressed miRNAs between metastatic and non-metastatic renal cell carcinoma at the time of nephrectomy.

Clinica Chim Acta. 416: 5-10Cochetti G. Cari L. Maulà V. et al.

Validation in an independent cohort of MiR-122, MiR-1271, and MiR-15b as urinary biomarkers for the potential early diagnosis of clear cell renal cell carcinoma.

Cancers. 14: 1112Terakawa T. Miyake H. Kusuda Y. et al.

Expression level of vascular endothelial growth factor receptor-2 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with sunitinib.

Urol Oncol Semin Original Invest. 31: 493-498Paule B. Bastien L. Deslandes E. et al.

Soluble isoforms of vascular endothelial growth factor are predictors of response to sunitinib in metastatic renal cell carcinomas.

PLoS One. 5https://doi.org/10.1371/journal.pone.0010715

What does PD-L1 positive or negative mean?.

J Exp Med. 213: 2835-2840Motzer R.J. Escudier B. McDermott D.F. et al.

Nivolumab versus everolimus in advanced renal-cell carcinoma.

N Engl J Med. 373: 1803-1813Motzer R.J. Tannir N.M. McDermott D.F. et al.

Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma.

N Engl J Med. 378: 1277-1290Rini B.I. Plimack E.R. Stus V. et al.

Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma.

N Engl J Med. 380: 1116-1127Rini B.I. Powles T. Atkins M.B. et al.

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.

Lancet. 393: 2404-2415Motzer R.J. Robbins P.B. Powles T. et al.

Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial.

Nat Med. 26: 1733-1741Voss M.H. Reising A. Cheng Y. et al.

Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.

Lancet Oncol. 19: 1688-1698Brooks S.A. Brannon A.R. Parker J.S. et al.

ClearCode34: a prognostic risk predictor for localized clear cell renal cell carcinoma.

Eur Urol. 66: 77-84Serie D.J. Joseph R.W. Cheville J.C. et al.

Clear cell type A and B molecular subtypes in metastatic clear cell renal cell carcinoma: tumor heterogeneity and aggressiveness.

Eur Urol. 71: 979-985Morgan T.M. Mehra R. Tiemeny P. et al.

A multigene signature based on cell cycle proliferation improves prediction of mortality within 5 yr of radical nephrectomy for renal cell carcinoma.

Eur Urol. 73: 763-769Brannon A.R. Reddy A. Seiler M. et al.

Molecular stratification of clear cell renal cell carcinoma by consensus clustering reveals distinct subtypes and survival patterns.

Genes & Cancer. 1: 152-163Şenbabaoğlu Y. Gejman R.S. Winer A.G. et al.

Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures.

Genome Biol. 17: 231Braun D.A. Hou Y. Bakouny Z. et al.

Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma.

Nat Med. 26: 909-918Miao D. Margolis C.A. Gao W. et al.

Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma.

Science. 359: 801-806Braun D.A. Ishii Y. Walsh A.M. et al.

Clinical validation of PBRM1 alterations as a marker of immune checkpoint inhibitor response in renal cell carcinoma.

JAMA Oncol. 5: 1631-1633Liu X.D. Kong W. Peterson C.B. et al.

PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma.

Nat Commun. 11: 2135Hakimi A.A. Attalla K. DiNatale R.G. et al.

A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy response.

Nat Commun. 11: 4168Rappold P.M. Silagy A.W. Kotecha R.R. et al.

Immune checkpoint blockade in renal cell carcinoma.

J Surg Oncol. 123: 739-750McDermott D.F. Huseni M.A. Atkins M.B. et al.

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.

Nat Med. 24: 749-757Braun D.A. Bakouny Z. Hirsch L. et al.

Beyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma.

Nat Rev Clin Oncol. 18: 199-214Hakimi A.A. Voss M.H. Kuo F. et al.

Transcriptomic profiling of the tumor microenvironment reveals distinct subgroups of clear cell renal cell cancer: data from a randomized phase III trial.

Cancer Discov. 9: 510-525Rappold P.M. Vuong L. Leibold J. et al.

A targetable myeloid inflammatory state governs disease recurrence in clear cell renal cell carcinoma.

Cancer Discov. https://doi.org/10.1158/2159-8290.CD-21-0925